J&J Monistat 1 joins Vagistat-1 in one-day yeast infection treatment market.
This article was originally published in The Tan Sheet
Executive Summary
MONISTAT 1 ENTERING ONE-DAY YEAST INFECTION TREATMENT MARKET under a licensing agreement between Johnson & Johnson and Bristol-Myers Squibb, the patent holder of the 6.5% tioconazole formulation. Bristol-Myers' Vagistat-1, which also contains 6.5% tioconazole, has been the sole entrant in the one-day vaginal yeast infection market until now. In stores nationwide starting June 15, Monistat 1 is being distributed by J&J's Personal Products Company.
You may also be interested in...
J&J Monistat 3 Combination Pack Cream Extension Clears FDA
Johnson & Johnson Personal Products will begin shipping a Monistat 3 Combination Pack cream line extension to food, drug and mass outlets in the second quarter, the firm said Feb. 9.
J&J Monistat 3 Combination Pack Cream Extension Clears FDA
Johnson & Johnson Personal Products will begin shipping a Monistat 3 Combination Pack cream line extension to food, drug and mass outlets in the second quarter, the firm said Feb. 9.
J&J Monistat 3 Combination Pack Cream Extension Clears FDA
Johnson & Johnson Personal Products will begin shipping a Monistat 3 Combination Pack cream line extension to food, drug and mass outlets in the second quarter, the firm said Feb. 9.